(3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide; sulfuric acid/Larotinib
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Larotinib is an investigational tyrosine kinase inhibitor targeting specific oncogenic pathways. Its core synthesis involves advanced heterocyclic coupling. <strong>Molecular Formula</strong>: C21H25ClN4O; <strong>CAS No.</strong>: 197608-34-9.</p>
<h3>Application</h3>
<ul>
<li>Oncology: Clinical trials for solid tumors with EGFR mutations.</li>
<li>R&D: Preclinical screening for drug discovery pipelines.</li>
<li>Pharma Manufacturing: Intermediate synthesis for targeted therapies.</li>
</ul>
<h3>Precautions</h3>
<p>Restricted to authorized research facilities only. Requires PPE during handling and storage at -20°C in desiccated conditions to maintain stability.</p>